US equities |
NVDA $237.48 ▲+1.51% MU $1,061.96 ▼-1.20% SPCX $164.64 ▲+3.57% TSLA $376.09 ▲+1.48% MSFT $527.45 ▲+1.92% INTC $116.47 ▼-2.40% SNDK $1,718.24 ▼-0.10% AMD $630.02 ▼-0.61%
FinancialContent

Articles published by CURE Pharmaceutical Holding Corp.

News headline image
CURE Pharmaceutical Receives Patent Approval for Its CUREfilm Blue™ Technology
From CURE Pharmaceutical Holding Corp.
Via Business Wire
Tickers OTC
News headline image
CURE Pharmaceutical Reports Second Quarter 2021 Revenue Rose Nearly 700% Driven by Sales from Sera Labs Product Lines
From CURE Pharmaceutical Holding Corp.
Via Business Wire
Tickers CURR
News headline image
CURE Pharmaceutical to Present at H.C. Wainwright 2021 Psychedelics in Psychiatry and Beyond Virtual Conference
From CURE Pharmaceutical Holding Corp.
Via Business Wire
Tickers CURR
News headline image
CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Veteran Health
From CURE Pharmaceutical Holding Corp.
Via Business Wire
Tickers CURR
News headline image
CURE Pharmaceutical Schedules Investor Webcast for Thursday, May 27, 2021
From CURE Pharmaceutical Holding Corp.
Via Business Wire
Tickers CURR
News headline image
CURE Pharmaceutical First Quarter Revenue Quadruples to $1.5 million; Company Expands Clinical Pipeline to Include Psychedelics
From CURE Pharmaceutical Holding Corp.
Via Business Wire
Tickers CURR
News headline image
CURE Pharmaceutical Receives ISO Certification for Laboratory and Manufacturing Facility
From CURE Pharmaceutical Holding Corp.
Via Business Wire
Tickers CURR
News headline image
CURE Pharmaceutical Announces Successful Results From Initial Clinical Trials for Erectile Dysfunction Product CUREfilm Blue™
From CURE Pharmaceutical Holding Corp.
Via Business Wire
Tickers CURR
News headline image
CURE Pharmaceutical to Present at the 2021 Sequire Cannabis Conference on Tuesday, April 20, at 2 p.m. EDT/11 a.m. PDT
From CURE Pharmaceutical Holding Corp.
Via Business Wire
Tickers OTC